Passage BIO, Inc.
PASG- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001787297
No open-market purchases or sales by Passage BIO, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $6.82M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 11, 2026, 1:16 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 10, 2025 | Mar 4, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Research and development | $23.3M | $40.2M | $61.4M | $86.1M | $117.7M |
| Selling, general and administrative | $19.9M | $25.0M | $41.6M | $49.3M | $60.1M |
| Operating income | -$49.3M | -$70.4M | -$108.4M | -$138.4M | -$185.7M |
| Income tax | $0 | – | – | – | – |
| Net income | -$45.5M | -$64.8M | -$102.1M | -$136.1M | -$185.4M |
| EPS, basic | $-14.35 | $-1.07 | $-1.86 | $-2.50 | $-3.48 |
| EPS, diluted | $-14.35 | $-1.07 | $-1.86 | $-2.50 | $-3.48 |
| Weighted shares, basic | 3.17M | 60.4M | 54.7M | 54.4M | 53.3M |
| Weighted shares, diluted | 3.17M | 60.4M | 54.7M | 54.4M | 53.3M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 10, 2025 | Mar 4, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Cash and equivalents | $46.3M | $37.6M | $21.7M | $34.6M | $129.0M |
| Total current assets | $47.8M | $78.8M | $118.0M | $197.0M | $325.1M |
| Property, plant and equipment | $4.11M | $9.33M | $15.3M | $22.5M | $23.8M |
| Total assets | $62.3M | $102.4M | $150.5M | $243.5M | $355.1M |
| Accounts payable | $1.11M | $742.0K | $1.30M | $4.07M | $9.45M |
| Total current liabilities | $23.1M | $19.4M | $16.3M | $18.4M | $29.5M |
| Total liabilities | $43.5M | $41.2M | $39.3M | $42.2M | $36.4M |
| Shareholders' equity | $18.8M | $61.3M | $111.3M | $201.4M | $318.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 10, 2025 | Mar 4, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Operating cash flow | -$31.5M | -$48.0M | -$78.3M | -$118.2M | -$126.9M |
| Depreciation and amortization | $728.0K | $3.08M | $3.72M | $3.68M | $1.54M |
| Stock-based compensation | $3.00M | $5.82M | $10.9M | $19.0M | $32.7M |
| Investing cash flow | $40.2M | $54.9M | $65.2M | $25.2M | -$45.8M |
| Financing cash flow | $23.0K | $8.87M | $135.0K | -$1.35M | $166.7M |
| Net change in cash | $8.73M | $15.9M | -$12.9M | -$94.4M | -$6.04M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 6, 2026 | 3.22M | +1.2% | SEC |
| Aug 5, 2026 | 3.22M | +1.2% | SEC |
| May 7, 2026 | 3.21M | −94.8% | SEC |
| Feb 26, 2026 | 3.21M | −94.8% | SEC |
| Nov 6, 2025 | 3.18M | −94.9% | SEC |
| Aug 7, 2025 | 3.18M | −94.9% | SEC |
| May 8, 2025 | 62.1M | +0.8% | SEC |
| Feb 27, 2025 | 62.1M | +11.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-20 in Q3 2025.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.